Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec®
|
21 October 2009 |
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
|
13 October 2009 |
Sandoz launches somatropin, the first-ever Japanese biosimilar
|
06 October 2009 |
Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
|
02 October 2009 |
Novartis bronchodilator QAB149 recommended for approval in European Union
|
28 September 2009 |
Novartis investigational bronchodilator QAB149 compared to tiotropium
|
17 September 2009 |
Novartis MF59® vaccine shows strong immune response in A(H1N1) clinical trials
|
04 September 2009 |
Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
|
21 August 2009 |
US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis
|
19 August 2009 |
Sandoz launches first generic version of Prograf® capsules
|
12 August 2009 |